LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company,
announced publication of abstracts on neratinib for the American
Association for Cancer Research (AACR) Annual Meeting 2016. The AACR
Annual Meeting will be held at the Ernest N. Morial Convention Center in
New Orleans from April 16 to April 20.
Sun, Apr 17, 1:00 – 5:00 p.m. CDT – Abstract 298, Section 16,
Poster Board 9: Amplification of mutant ERBB2 drives resistance to the
irreversible kinase inhibitor neratinib in ERBB2-mutated breast cancer
patients.
FJ Carmona, D Hyman, G Ulaner, J Erinjeri, N Bouvier, H
Won, R Cutler, A Alani, M Berger, J Baselga, M Scaltriti.
Tue, Apr 19, 8:00 a.m. – 12:00 p.m. CDT – Abstract 3140, Section
22, Poster Board 7: Differential clonal selection in tumor tissue and
cell-free DNA from a neratinib-treated refractory breast cancer patient
harboring an activating ERBB2 (HER2) mutation.
L Joenson, CW Yde, O
Østrup, M Mau-Sørensen, FC Nielsen, U Lassen
Wed, Apr 20, 8:00 a.m. – 12:00 p.m. CDT – Abstract 4760, Poster
Board 11: Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models
harboring known and novel HER2-mutations.
MJ Wick, M Farley, T
Vaught, J Meade, M Glassman, A Moriarty, AW Tolcher, D Rasco, A Patnaik,
KP Papadopoulos
The abstracts are available online at: http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=63&DetailItemID=363#.Vusrr-IrKUk.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the development and commercialization of innovative products to enhance
cancer care. The Company in-licenses the global development and
commercialization rights to three drug candidates—PB272 (neratinib
(oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a
potent irreversible tyrosine kinase inhibitor that blocks signal
transduction through the epidermal growth factor receptors, HER1, HER2
and HER4. Currently, the Company is primarily focused on the development
of the oral version of neratinib, and its most advanced drug candidates
are directed at the treatment of HER2-positive breast cancer. The
Company believes that neratinib has clinical application in the
treatment of several other cancers as well, including non-small cell
lung cancer and other tumor types that over-express or have a mutation
in HER2.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
Forward-Looking Statements:
This press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and actual
outcomes and results could differ materially from these statements due
to a number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic reports filed by the Company with the
Securities and Exchange Commission from time to time. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company assumes
no obligation to update these forward-looking statements, except as
required by law.
Contact: